Quark Aims for Five Clinical Indications, New IND in 2010

The company also anticipates at least one of its drugs will move into phase III testing by the end of 2010, a milestone that could put it in a position to make a second attempt at going public.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.